Research has shown that buprenorphine can decrease the risk of neonatal abstinence syndrome in pregnant patients. NAS is a condition that affects developing fetuses in the womb and babies immediately upon childbirth. Essentially, a patient and their unborn child both absorb opioids through pregnancy. Once the child is born, they will experience withdrawals just as someone with OUD would upon abruptly stopping use. NAS also carries other risks such as low birth weight, developmental problems, seizures, sudden infant death syndrome, and more. Pregnant patients will work with their AppleGate Recovery medical provider and collaborating obstetrical care. During this time, patients won’t incur additional monthly treatment fees as the pregnancy progresses.